Response Predictivity to Neoadjuvant Therapies in Breast Cancer: A Qualitative Analysis of Background Parenchymal Enhancement in DCE-MRI
Authors:
- Daniele La ForgiaDaniele La Forgia
- Angela VestitoAVAngela Vestito
- Maurilia LasciarreaMLMaurilia Lasciarrea
- Maria Colomba ComesMCMaria Colomba Comes
- Sergio DiotaiutiSDSergio Diotaiuti
- Francesco GiottaFGFrancesco Giotta
- Agnese LatorreALAgnese Latorre
- Vito LorussoVito Lorusso
- Raffaella MassafraRaffaella Massafra
- Gennaro PalmiottiGPGennaro Palmiotti
- Lucia RinaldiLRLucia Rinaldi
- Rahel SignorileRSRahel Signorile
Open Access
- 1 April 2021
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (4) , 256
Abstract
Background: For assessing the predictability of oncology neoadjuvant therapy results, the background parenchymal enhancement (BPE) parameter in breast magnetic resonance imaging (MRI) has acquired increased interest. This work aims to qualitatively evaluate the BPE parameter as a potential predictive marker for neoadjuvant therapy. Method: Three radiologists examined, in triple-blind modality, the MRIs of 80 patients performed before the start of chemotherapy, after three months from the start of treatment, and after surgery. They identified the portion of fibroglandular tissue (FGT) and BPE of the contralateral breast to the tumor in the basal control pre-treatment (baseline). Results: We observed a reduction of BPE classes in serial MRI checks performed during neoadjuvant therapy, as compared to baseline pre-treatment conditions, in 61.3% of patients in the intermediate step, and in 86.7% of patients in the final step. BPE reduction was significantly associated with sequential anthracyclines/taxane administration in the first cycle of neoadjuvant therapy compared to anti-HER2 containing therapies. The therapy response was also significantly related to tumor size. There were no associations with menopausal status, fibroglandular tissue (FGT) amount, age, BPE baseline, BPE in intermediate, and in the final MRI step. Conclusions: The measured variability of this parameter during therapy could predict therapy effectiveness in early stages, improving decision-making in the perspective of personalized medicine. Our preliminary results suggest that BPE may represent a predictive factor in response to neoadjuvant therapy in breast cancer, warranting future investigations in conjunction with radiomics.Keywords
This publication has 41 references indexed in Scilit:
- Breast MRI background parenchymal enhancement (BPE) correlates with the risk of breast cancerMagnetic Resonance Imaging, 2016
- Are Qualitative Assessments of Background Parenchymal Enhancement, Amount of Fibroglandular Tissue on MR Images, and Mammographic Density Associated with Breast Cancer Risk?Radiology, 2015
- Background Parenchymal Enhancement of the Contralateral Normal Breast: Association with Tumor Response in Breast Cancer Patients Receiving Neoadjuvant ChemotherapyTranslational Oncology, 2015
- Inter- and Intrareader Agreement for Categorization of Background Parenchymal Enhancement at Baseline and After TrainingAmerican Journal of Roentgenology, 2014
- Background Parenchymal Signal Enhancement Ratio at Preoperative MR Imaging: Association with Subsequent Local Recurrence in Patients with Ductal Carcinoma in Situ after Breast Conservation SurgeryRadiology, 2014
- Background Parenchymal Enhancement at Breast MR Imaging: Normal Patterns, Diagnostic Challenges, and Potential for False-Positive and False-Negative InterpretationRadioGraphics, 2014
- The Impact of Bilateral Salpingo-Oophorectomy on Breast MRI Background Parenchymal Enhancement and Fibroglandular TissueEuropean Radiology, 2013
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRIEuropean Radiology, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009